Skip to main content
Pharming Group N.V. logo

Pharming Group N.V. — Investor Relations & Filings

Ticker · PHARM ISIN · NL0010391025 LEI · 724500DCJ9MPG74JEH91 AS Manufacturing
Open in API
Filings indexed 800 across all filing types
Latest filing 2012-08-08 Capital/Financing Update
Country NL Netherlands
Listing AS PHARM

About Pharming Group N.V.

https://www.pharming.com/

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.

Recent filings

Filing Released Lang Actions
Pharming draws first tranche under €10 million working capital facility
Capital/Financing Update Classification · 98% confidence The document is a press release dated August 8, 2012, announcing two key events: 1) Drawing the first tranche under a €10 million working capital facility, which involves issuing new shares, and 2) Providing an update on the RUCONEST® Phase III Study progress and associated milestones. The announcement of issuing new shares directly relates to capital structure changes and fundraising activities. This aligns best with the 'Capital/Financing Update' category (CAP). It is not a full Annual Report (10-K), an Earnings Release (ER) focusing only on results, or a formal Audit Report (AR). Since it is a specific announcement about financing and capital changes, CAP is the most precise fit.
2012-08-08 English
Directorate change
Board/Management Information Classification · 99% confidence The document explicitly uses the heading "DIRECTORATE CHANGE" and announces that the Chief Financial Officer (CFO), Karl Keegan, is leaving the Company and resigning from the Board of Management. This directly corresponds to the definition of Board/Management Information, which covers announcements of changes in the company's board of directors or senior management.
2012-08-06 English
Pharming announces restructuring plan
Regulatory Filings Classification · 95% confidence The document is titled "PHARMING ANNOUNCES RESTRUCTURING PLAN" and details strategic operational changes, including filing for collective redundancies with Dutch authorities (UWV Werkbedrijf). It also provides updates on the RUCONEST® Phase III study and its path to FDA BLA submission. This content structure—announcing significant business strategy changes, cost reduction plans, and operational updates alongside clinical trial progress—is characteristic of a press release or an official announcement intended for the market and investors, rather than a formal regulatory filing like a 10-K or a comprehensive quarterly report (IR). Since it is a formal announcement of business events and strategy, it fits best under the general category for significant corporate news that isn't strictly financial results (ER) or management changes (MANG). Given the options, this is a general corporate announcement. If it were a formal filing detailing the restructuring plan itself, it might be LTR or RNS, but as a high-level announcement of the plan and related business updates, it aligns most closely with a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it were tied to a specific reporting period's results, which it is not. However, since it is a press release announcing major corporate actions (restructuring, clinical trial progress), and RNS is the general regulatory/miscellaneous filing category, RNS is the most appropriate fit for a non-standard, non-financial-results press release.
2012-08-02 English
Pharming secures €10 million working capital facility from existing investors
Capital/Financing Update Classification · 98% confidence The document is an announcement dated August 1, 2012, detailing that Pharming Group NV has secured a working capital facility of up to €10 million from existing investors. The core subject is a financing activity involving drawing down funds in exchange for shares and warrants. This directly aligns with the definition of 'Capital/Financing Update' (CAP), which covers company fundraising and capital structure changes. It is not an Annual Report (10-K), an Earnings Release (ER), or a formal Audit Report (AR).
2012-08-01 English
Pharming confirms safety profile of recombinant human Lactoferrin in a food safety study in healthy human volunteers
Regulatory Filings Classification · 93% confidence The document is a press release dated July 16, 2012, announcing the safety profile confirmation of Pharming's recombinant human Lactoferrin (rhLF) based on a completed clinical study in healthy volunteers. It details the study parameters, confirms safety, and mentions ongoing out-licensing discussions. This type of announcement, focusing on the results of a specific study or development milestone, is characteristic of an Earnings Release (ER) if it were quarterly results, but since it is a specific scientific/development update, it fits best under the general category of a corporate announcement that is not a formal financial report (like 10-K or IR) or a specific management/board change. Given the options, it is a general corporate update that doesn't fit the highly specific categories like DIRS, DIV, or CAP. It is not a transcript (CT), a formal report (10-K, IR), or a presentation (IP). It is most closely aligned with an Earnings Release (ER) in function (announcing key operational/development news) or, if that is too specific for non-financial results, the general Regulatory Filings (RNS) fallback. Since it is a direct announcement of a key development milestone, ER is often used for significant operational news, but RNS is the safest fallback for non-standard announcements. However, looking closely at the definitions, ER is for 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This is a clinical safety result announcement. Therefore, the most appropriate category for a non-financial, non-statutory, but important corporate update that doesn't fit elsewhere is the general Regulatory Filings category (RNS).
2012-07-16 English
Pharming updates on shares in issue
Share Issue/Capital Change Classification · 98% confidence The document is a press release dated July 6, 2012, announcing that Pharming Group NV issued shares to bondholders as a final redemption payment. The core subject is the change in the number of outstanding shares, specifically stating: 'As of today, the number of outstanding shares has increased from 688,992,651 to 724,248,676.' This directly relates to a change in the capital structure or share count. Reviewing the definitions, 'Share Issue/Capital Change (Code: SHA)' is the most appropriate category for announcements detailing the issuance of new shares and the resulting change in the total outstanding share count. Although it involves debt redemption, the primary announcement focuses on the resulting equity change.
2012-07-06 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.